As of 2025-10-17, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -3.24. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 270.04 mil USD. KPTI's TTM EBITDA according to its financial statements is -83.37 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.6x - 12.3x | 11.0x |
| Forward P/E multiples | 15.9x - 19.5x | 18.3x |
| Fair Price | (178.00) - (143.58) | (165.98) |
| Upside | -3052.0% - -2481.1% | -2852.6% |
| Date | EV/EBITDA |
| 2025-10-16 | -3.24 |
| 2025-10-15 | -3.23 |
| 2025-10-14 | -3.21 |
| 2025-10-13 | -3.20 |
| 2025-10-10 | -3.18 |
| 2025-10-09 | -3.22 |
| 2025-10-08 | -3.23 |
| 2025-10-07 | -3.21 |
| 2025-10-06 | -3.25 |
| 2025-10-03 | -3.28 |
| 2025-10-02 | -3.27 |
| 2025-10-01 | -3.26 |
| 2025-09-30 | -3.29 |
| 2025-09-29 | -3.27 |
| 2025-09-26 | -3.29 |
| 2025-09-25 | -3.30 |
| 2025-09-24 | -3.33 |
| 2025-09-23 | -3.39 |
| 2025-09-22 | -3.22 |
| 2025-09-19 | -3.17 |
| 2025-09-18 | -3.21 |
| 2025-09-17 | -3.24 |
| 2025-09-16 | -3.26 |
| 2025-09-15 | -3.26 |
| 2025-09-12 | -3.28 |
| 2025-09-11 | -3.30 |
| 2025-09-10 | -3.26 |
| 2025-09-09 | -3.27 |
| 2025-09-08 | -3.26 |
| 2025-09-05 | -3.30 |
| 2025-09-04 | -3.31 |
| 2025-09-03 | -3.35 |
| 2025-09-02 | -3.32 |
| 2025-08-29 | -3.35 |
| 2025-08-28 | -3.41 |
| 2025-08-27 | -3.42 |
| 2025-08-26 | -3.39 |
| 2025-08-25 | -3.27 |
| 2025-08-22 | -3.27 |
| 2025-08-21 | -3.24 |
| 2025-08-20 | -3.29 |
| 2025-08-19 | -3.26 |
| 2025-08-18 | -3.19 |
| 2025-08-15 | -3.23 |
| 2025-08-14 | -3.10 |
| 2025-08-13 | -3.07 |
| 2025-08-12 | -3.03 |
| 2025-08-11 | -3.00 |
| 2025-08-08 | -3.02 |
| 2025-08-07 | -3.02 |